213 related articles for article (PubMed ID: 27729184)
1. Deficiency of the complement regulatory protein CD59 accelerates the development of diabetes-induced atherosclerosis in mice.
Liu F; Sahoo R; Ge X; Wu L; Ghosh P; Qin X; Halperin JA
J Diabetes Complications; 2017 Feb; 31(2):311-317. PubMed ID: 27729184
[TBL] [Abstract][Full Text] [Related]
2. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex.
Wu G; Hu W; Shahsafaei A; Song W; Dobarro M; Sukhova GK; Bronson RR; Shi GP; Rother RP; Halperin JA; Qin X
Circ Res; 2009 Feb; 104(4):550-8. PubMed ID: 19131645
[TBL] [Abstract][Full Text] [Related]
3. CD59 but not DAF deficiency accelerates atherosclerosis in female ApoE knockout mice.
An G; Miwa T; Song WL; Lawson JA; Rader DJ; Zhang Y; Song WC
Mol Immunol; 2009 May; 46(8-9):1702-9. PubMed ID: 19297024
[TBL] [Abstract][Full Text] [Related]
4. TLR4 antagonist reduces early-stage atherosclerosis in diabetic apolipoprotein E-deficient mice.
Lu Z; Zhang X; Li Y; Jin J; Huang Y
J Endocrinol; 2013 Jan; 216(1):61-71. PubMed ID: 23060524
[TBL] [Abstract][Full Text] [Related]
5. Urotensin II receptor antagonism confers vasoprotective effects in diabetes associated atherosclerosis: studies in humans and in a mouse model of diabetes.
Watson AM; Olukman M; Koulis C; Tu Y; Samijono D; Yuen D; Lee C; Behm DJ; Cooper ME; Jandeleit-Dahm KA; Calkin AC; Allen TJ
Diabetologia; 2013 May; 56(5):1155-65. PubMed ID: 23344731
[TBL] [Abstract][Full Text] [Related]
6. Molecular mechanism of inhibitory effects of CD59 gene on atherosclerosis in ApoE (-/-) mice.
Li B; Xu YJ; Chu XM; Gao MH; Wang XH; Nie SM; Yang F; Lv CY
Immunol Lett; 2013; 156(1-2):68-81. PubMed ID: 24084445
[TBL] [Abstract][Full Text] [Related]
7. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice.
Lewis RD; Jackson CL; Morgan BP; Hughes TR
Mol Immunol; 2010 Feb; 47(5):1098-105. PubMed ID: 19959238
[TBL] [Abstract][Full Text] [Related]
8. Oral chromium picolinate impedes hyperglycemia-induced atherosclerosis and inhibits proatherogenic protein TSP-1 expression in STZ-induced type 1 diabetic ApoE
Ganguly R; Sahu S; Ohanyan V; Haney R; Chavez RJ; Shah S; Yalamanchili S; Raman P
Sci Rep; 2017 Mar; 7():45279. PubMed ID: 28345659
[TBL] [Abstract][Full Text] [Related]
9. Brief report: accelerated atherosclerosis in low-density lipoprotein receptor-deficient mice lacking the membrane-bound complement regulator CD59.
Yun S; Leung VW; Botto M; Boyle JJ; Haskard DO
Arterioscler Thromb Vasc Biol; 2008 Oct; 28(10):1714-6. PubMed ID: 18617646
[TBL] [Abstract][Full Text] [Related]
10. Irisin protects against endothelial injury and ameliorates atherosclerosis in apolipoprotein E-Null diabetic mice.
Lu J; Xiang G; Liu M; Mei W; Xiang L; Dong J
Atherosclerosis; 2015 Dec; 243(2):438-48. PubMed ID: 26520898
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis for a link between complement and the vascular complications of diabetes.
Acosta J; Hettinga J; Flückiger R; Krumrei N; Goldfine A; Angarita L; Halperin J
Proc Natl Acad Sci U S A; 2000 May; 97(10):5450-5. PubMed ID: 10805801
[TBL] [Abstract][Full Text] [Related]
12. Complement regulator CD59 protects against angiotensin II-induced abdominal aortic aneurysms in mice.
Wu G; Chen T; Shahsafaei A; Hu W; Bronson RT; Shi GP; Halperin JA; Aktas H; Qin X
Circulation; 2010 Mar; 121(11):1338-46. PubMed ID: 20212283
[TBL] [Abstract][Full Text] [Related]
13. PKCβ promotes vascular inflammation and acceleration of atherosclerosis in diabetic ApoE null mice.
Kong L; Shen X; Lin L; Leitges M; Rosario R; Zou YS; Yan SF
Arterioscler Thromb Vasc Biol; 2013 Aug; 33(8):1779-87. PubMed ID: 23766264
[TBL] [Abstract][Full Text] [Related]
14. Role of complement and complement regulatory proteins in the complications of diabetes.
Ghosh P; Sahoo R; Vaidya A; Chorev M; Halperin JA
Endocr Rev; 2015 Jun; 36(3):272-88. PubMed ID: 25859860
[TBL] [Abstract][Full Text] [Related]
15. Advanced glycation end-product Nε-carboxymethyl-Lysine accelerates progression of atherosclerotic calcification in diabetes.
Wang Z; Jiang Y; Liu N; Ren L; Zhu Y; An Y; Chen D
Atherosclerosis; 2012 Apr; 221(2):387-96. PubMed ID: 22305260
[TBL] [Abstract][Full Text] [Related]
16. Generation and phenotyping of mCd59a and mCd59b double-knockout mice.
Qin X; Hu W; Song W; Grubissich L; Hu X; Wu G; Ferris S; Dobarro M; Halperin JA
Am J Hematol; 2009 Feb; 84(2):65-70. PubMed ID: 19051264
[TBL] [Abstract][Full Text] [Related]
17. The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.
Nakatsu Y; Kokubo H; Bumdelger B; Yoshizumi M; Yamamotoya T; Matsunaga Y; Ueda K; Inoue Y; Inoue MK; Fujishiro M; Kushiyama A; Ono H; Sakoda H; Asano T
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28777298
[TBL] [Abstract][Full Text] [Related]
18. Glyoxalase 1 overexpression does not affect atherosclerotic lesion size and severity in ApoE-/- mice with or without diabetes.
Hanssen NM; Brouwers O; Gijbels MJ; Wouters K; Wijnands E; Cleutjens JP; De Mey JG; Miyata T; Biessen EA; Stehouwer CD; Schalkwijk CG
Cardiovasc Res; 2014 Oct; 104(1):160-70. PubMed ID: 25139743
[TBL] [Abstract][Full Text] [Related]
19. Targeted mouse complement inhibitor CR2-Crry protects against the development of atherosclerosis in mice.
Liu F; Wu L; Wu G; Wang C; Zhang L; Tomlinson S; Qin X
Atherosclerosis; 2014 May; 234(1):237-43. PubMed ID: 24685815
[TBL] [Abstract][Full Text] [Related]
20. Reduced atherosclerotic lesions in P2Y1/apolipoprotein E double-knockout mice: the contribution of non-hematopoietic-derived P2Y1 receptors.
Hechler B; Freund M; Ravanat C; Magnenat S; Cazenave JP; Gachet C
Circulation; 2008 Aug; 118(7):754-63. PubMed ID: 18663083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
